Maligna custos is a microscopic, living organism designed to be injected once into the human body. Its purpose is absolute: to seek out and kill cancer cells directly, leaving no residue, no poison, and no harm to healthy tissue. When the cancer is gone, it does not die. It goes dormant—a quiet sentinel inside the body, watching. If cancer ever returns, it reawakens, regenerates, and fights again.
It is not a drug. It is not a chemical. It is a living species born from a single idea: make the body permanently hostile to cancer.
Cancer is the body's own cells turned against it. They forget how to die. They multiply without limit. They hide from the immune system, build their own blood supply, and spread. Current medicine poisons the body to kill the cancer—chemotherapy, radiation, surgery—leaving damage and residue. And even then, cancer often returns.
Maligna custos takes another path. It kills only the cancer. It adapts to resistance. It remembers the cancer's signature. And it waits—years, decades—ready to strike again if the cancer ever comes back.
Maligna custos did not begin fully formed. It began as a vision: a living organism that could do what no drug can do—cure cancer completely and permanently.
We mapped its full anatomy: ten killing functions, thirteen structural components, safeguards against mutation and weaponization. We attempted to simulate its behavior. But cancer is too complex, too adaptive, too deeply tied to the individual human body to be honestly modeled in a computer. Our simulations produced impossible results—too fast, too simple, too perfect. We discarded them.
That is not failure. It is honesty. Some species cannot be proven by code. They must be proven by biology.
So the design is documented. The species is complete. It awaits laboratory testing—the only path to true validation.
Maligna custos is designed to do ten things at once:
Computer simulation was attempted and found to be insufficient for a species of this complexity. Cancer is too variable, too adaptive, and too deeply embedded in human biology for a simplified simulation to be honest.
Therefore, validation is pending laboratory testing. The full experimental protocol has been documented. It includes in vitro testing against cancer cell lines, tumor tissue penetration studies, animal trials under ethical oversight, and ultimately human clinical trials.
No fake results will be published. The species stands on its design and on the future biological work that will prove it.
| Tier | Fee | Usage |
|---|---|---|
| Personal | $97 | Study only. |
| Clinical / Pilot | $2,997 | One clinic or pilot program. |
| Enterprise / Hospital | $19,997 | Full hospital or regional rights. |
| Exclusive Territory | $50,000+ | Exclusive rights, negotiated. |
| Volume Tier | Royalty per Dose |
|---|---|
| First 100 doses | $500 |
| Next 400 doses | $400 |
| Over 500 doses | $300 |
All licenses are leases. Ownership remains with Family Tree Trust. The full formula and activator are trade secrets. Only measured portions are supplied. Validation pending laboratory testing; licensing available for research institutions and clinical partners.
This species is leased, not sold. All rights remain with Family Tree Trust. Wagg is the distributor.
Payment: Cash App: $wagg216
Contact: ctwllc60@gmail.com